Respectfully - how are you going to prevent .03 - .05, as my very conservative estimates show:
April 23, SEC case expected to be tossed.
May 9 Tentative FDA meeting.
Q1 (May15) 100k-200k units not surprised by an even higher number.
Sometime in June/July we’ll hear the results of both the SEC hearing and the FDA additional clearances announcement(s).
Q2 (Aug 15) sales of near 1M.
Then I expect HUGE numbers to start rolling in because France & Germany are already in motion and we haven’t heard boo about the USA market yet. This is mainly overseas.
I’m not going to get too far ahead of myself, because there isn’t any news to report YET. Many potential deals probably pending our additional clearances.
So I think mid term .03 - .05 is easily justified without any PE ratios needed.
The main thing you may need to do is consider that most CHRONIC pain users will use more than 1 unit at a time. I wear between 2 and 4 units pretty regularly. And how many times are they reloading, 3x a year? 5x? 8x?
Just my 2 cents
Market Data 
Markets 
AI
